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Immune modulationBackground: Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that causes a deﬁcit of pancreatic
islet β cells. The complexities of overcoming autoimmunity in T1D have contributed to the challenges the re-
search community faceswhen devising successful treatments with conventional immune therapies. Overcoming
autoimmune T cell memory represents one of the key hurdles.
Methods: In this open-label, phase 1/phase 2 study, Caucasian T1D patients (N = 15) received two treatments
with the Stem Cell Educator (SCE) therapy, an approach that uses human multipotent cord blood-derived
multipotent stem cells (CB-SCs). SCE therapy involves a closed-loop system that brieﬂy treats the patient's lym-
phocytes with CB-SCs in vitro and returns the “educated” lymphocytes (but not the CB-SCs) into the patient's
blood circulation. This study is registered with ClinicalTrials.gov, NCT01350219.
Findings: Clinical data demonstrated that SCE therapy was well tolerated in all subjects. The percentage of naïve
CD4+ T cells was signiﬁcantly increased at 26 weeks and maintained through the ﬁnal follow-up at 56 weeks.
The percentage of CD4+ central memory T cells (TCM) was markedly and constantly increased at 18 weeks.
Both CD4+ effector memory T cells (TEM) and CD8
+ TEM cells were considerably decreased at 18 weeks and
26 weeks respectively. Additional clinical data demonstrated the modulation of C–C chemokine receptor 7
(CCR7) expressions on naïve T, TCM, and TEM cells. Following two treatments with SCE therapy, islet β-cell func-
tion was improved andmaintained in individuals with residual β-cell function, but not in those without residual
β-cell function.
Interpretation: Current clinical data demonstrated the safety and efﬁcacy of SCE therapy in immune modu-
lation. SCE therapy provides lasting reversal of autoimmune memory that could improve islet β-cell function in
Caucasian subjects.uman cord blood-derived multipotent stem cells; CCR7, C–C chemokine receptor 7; HbA1C, glycated hemoglobin; HLA, human
eactions; MNC,mononuclear cells; M2, muscarinic acetylcholine receptor 2; OGTT, oral glucose tolerance test; PBMC, peripheral
cator; S, stimulator; TCM, centralmemory T cells; TCR, T-cell receptor; TEM, effectormemory T cells; TGF-β1, transforming growth
gulatory T cells.
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Type 1 diabetes (T1D) is a major global health issue, and its inci-
dence is increasing. T1D is a T cell-mediated autoimmune disease that
reduces the population of pancreatic islet β cells, which limits insulin
production and interferes with glucose homeostasis. The immune dys-
function in T1D is complicated, with effects both in pancreatic islets
and outside the pancreas. Different components of the immune system
[e.g., CD4+, CD8+ T cells, Tregs, B cells, dendritic cells (DCs), monocyte/
macrophages (Mo/Mϕs), natural killer T cells (NKTs)] contribute to au-
toimmune responses in T1D, complicating efforts to develop successful
treatments or a cure that will work across most or all individuals with
the disease. Several recent clinical trials (Bach, 2011; Wherrett et al.,
2011) highlight the challenges in conquering T1D, but their failures pro-
vide some valuable lessons about the limitations of conventional im-
mune therapy and the future direction of the quest. Speciﬁcally, they
point to the need for an approach that produces comprehensive im-
mune modulation at both the local pancreatic and systematic levels
rather than targeting the pancreatic effects of one or a few components
of the immune system. The Stem Cell Educator therapy takes this
broader approach (Zhao and Mazzone, 2010; Zhao et al., 2012; Zhao,
2012; Zhao et al., 2013; Li et al., 2015).
Physiologically, the human immune system constantly protects the
body against a variety of pathogens thatmay be encountered. Following
the recognition and eradication of pathogens through adaptive immune
responses, the majority (90–95%) of T cells undergo apoptosis with the
remaining cells forming a pool of memory T cells, designated central
memory T cells (TCM), effectormemory T cells (TEM), and residentmem-
ory T cells (TRM) (Clark, 2015). In comparison to conventional T cells,
these memory T cells are long-lived with distinct phenotypes, such as
expression of speciﬁc surface markers, rapid production of different
cytokine proﬁles, capability of direct effector cell function, a different
potential for proliferation, and unique homing distribution patterns.
As a group, memory T cells display quick reactions upon re-exposure
to their cognate antigens in order to eliminate the reinfection of patho-
gens and restore balance and harmony of the immune system. Never-
theless, increasing evidence establishes that autoimmune memory T
cells become the “stumbling blocks” and hinder most attempts to treat
or cure autoimmune diseases, including T1D, multiple sclerosis (MS),
rheumatoid arthritis (RA), and system lupus erythematosus (SLE)
(Ehlers and Rigby, 2015; Clark, 2015; Devarajan and Chen, 2013).
Therefore, novel and more comprehensive approaches are needed to
fundamentally correct the inordinate dominance of autoimmune T cell
memory and overcome the complexities of autoimmune responses.
We previously characterized a new type of stem cell from human
cord blood, designated a cord blood-derived multipotent stem cell
(CB-SCs) (Zhao et al., 2006; Zhao and Mazzone, 2010). CB-SCs display
a unique phenotype with both embryonic and hematopoietic markers
that distinguish them from other known stem cell types, including
hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and
monocytes/macrophages (Mo/Mϕ) (Zhao et al., 2003). SCE therapy
functions as an “artiﬁcial thymus” that circulates a patient's blood
through a blood cell separator, brieﬂy treats the patient's lymphocytes
with CB-SCs in vitro, induces immune tolerance through the action of
autoimmune regulator (AIRE, expressed by CB-SCs), returns the educat-
ed autologous lymphocytes to the patient's circulation, and restores im-
mune balance and homeostasis (Zhao and Mazzone, 2010; Zhao et al.,
2012; Zhao, 2012). This approach was piloted in clinical studies for the
treatment of diabetes and other autoimmune diseases in China withpatients of Chinese origin (Zhao et al., 2012; Zhao, 2012; Zhao et al.,
2013; Li et al., 2015). Our clinical data demonstrates that the SCE thera-
py provides long-lasting reversal of autoimmunity that induces the re-
generation of pancreatic islet β cells and improvement of metabolic
control in individuals with longstanding T1D (Zhao et al., 2012). Find-
ings from recent autoimmune-causedAlopecia Areata (AA) trial provide
visible evidence that SCE therapy can control autoimmunity and lead to
the regeneration of tissues like hair regrowth (Li et al., 2015). Here, we
explored the expansion of the therapeutic potential of the SCE therapy
to the treatment of Caucasian T1D subjects in Spain.
2. Methods
2.1. Patients
T1D patients receiving care at the Endocrinology and Nutrition
Service, Hospital Universitario Central de Asturias (Oviedo, Spain)
were enrolled in this phase 1/phase 2, open-label clinical trial conduct-
ed from November 27, 2012 through October 1, 2014. The principal in-
vestigator designed the clinical trial and received ethical approval for
the clinical treatment protocol and consent form from Regional Com-
mittee for Clinical Research Ethics and the Comisión Permanente de
Trasplantes del Consejo Interterritorial del Sistema Nacional de Salud.
The signed informed consent was obtained from each participant.
The clinical trial was conducted in 15 subjects with established T1D
(Table 1). Subjects were qualiﬁed for recruitment if they met the 2012
diagnosis standards of the American Diabetes Association (ADA) and if a
blood test indicated the presence of at least one autoantibody to pan-
creatic islet β cells (Fig. 1). Key exclusion criteria included clinically
signiﬁcant liver (AST or ALT 2 ≥ x upper limit of normal), kidney (creati-
nine ≥ 2.0 mg/dl), or heart disease; pregnancy or breastfeeding mothers;
immunosuppressive medication; known active infection with viral dis-
eases; or diseases associated with immunodeﬁciency; or hemoglobin
b10 g/dl or platelets b100 k/ml; use of immunosuppressive medication
within one month.
2.2. SCE Therapy and Follow-up
All the participants received two treatments with the SCE (Tianhe
Stem Cell Biotechnology®, USA). The preparation of CB-SC cultures
and SCEs was performed as previously described (Zhao et al., 2012).
Brieﬂy, human cord blood units derived from healthy allogeneic donors
were obtained from Centro Comunitario de Sangre y Tejidos de Asturias
(CCST, Oviedo, Spain). All cord blood samples were screened for HIV
I&II, HBsAg, HBcAg, HCV, HIVNAT, STS, HBVNAT, HCVNAT, HTLV I/II,
West Nile, Chagas, and CMV, and only pathogen-free cord blood units
were used for clinical treatment. Human CB-SCs were produced as pre-
viously described (Zhao et al., 2006, 2009) with the followingmodiﬁca-
tions. Cord blood mononuclear cells were plated in SCE devices in
serum-free culture medium (Lonza, Walkersville, MD) and incubated
at 37 °C, in 8% CO2. After 2–3 weeks, CB-SCs growing at 90% conﬂuence
(about 107 cells/device) were prepared for clinical trial. CB-SCs were
characterized by ﬂow cytometry, using markers such as the leukocyte
common antigen CD45 and embryonic stem (ES) cell-speciﬁc transcrip-
tion factor OCT3/4 (Fig. S1). The measured endotoxin level was b0.05
EU/ml. One Educator device was generated from one cord blood unit,
and used for one subject at one treatment.
For the SCE therapy (Zhao et al., 2012, 2013), a 16-gauge IV needle
was placed in the left (or right) median cubital vein, and the patient's
Table 1
Characteristics of Caucasian T1D subjects before treatment.
Patient No. Age Gender History (year) Fasting C-peptide (ng/ml) Post-glucagon C-peptide (ng/ml) HbA1C (%) Insulin dose (U/kg body weight)
Group A: T1D patients with residual islet β cell function
1 36 M 1 0.77 1.06 7.1 0.28
2 27 F 1 0.54 0.57 6.3 0.32
3 31 F 10 0.25 0.4 9 0.52
4 20 M 3 1.05 2.18 6.2 0.18
5 37 M 14 0.26 0.36 7.8 0.4
6 52 M 10 0.23 0.27 9.2 0.61
Mean (SD) 33.8 (10.9) 6.5 (5.5) 0.52 (0.34) 0.81 (0.73) 7.6 (1.3) 0.38 (0.16)
Group B: T1D patients with no residual islet β cell function
7 30 M 23 b 0.01 b 0.01 7.1 0.62
8 37 M 15 b 0.01 b 0.01 6.2 0.72
9 40 F 12 b 0.01 b 0.01 8.4 0.92
10 53 F 14 b 0.01 b 0.01 9.1 0.79
11 33 M 13 b 0.01 b 0.01 7.4 0.56
12 48 F 6 b 0.01 0.04 10.1 0.58
13 32 M 6 b 0.01 0.01 8.3 0.51
14 45 M 17 b 0.01 b 0.01 6.5 0.71
15 45 M 6 0.02 0.06 8.4 0.96
Mean (SD) 40.3 (7.9) 12.4 (5.8) 0.01 (0.003) 0.02 (0.02) 7.9 (1.3) 0.71 (0.16)
2026 E. Delgado et al. / EBioMedicine 2 (2015) 2024–2036bloodwas passed through a Blood Cell Separator MCS+ (Haemonetics®,
Braintree,MA) to isolatemononuclear cells (MNC) in accordancewith the
manufacturer's recommended protocol. For a single session of MNC
collection by apheresis, approximately 10 l of blood was processed
from each enrolled subject within 6–7 h, with the collection of
about 1 × 1010 MNCs. The isolated mononuclear cells were trans-
ferred into the SCE device for the treatment with allogeneic CB-SCs,
and other blood components were automatically returned to the
patient's circulation. In the SCE device, MNC ioslated from a patient's
peripheral blood were slowly passed through the stacked discs with
adherent CB-SCs at the CB-SCs:MNC ratios from 1:20 to 1:50. AfterFig. 1. Study ﬂinteraction for 2–3 h (Fig. S2), CB-SC-treated mononuclear cells
were returned to the patient's blood circulation via a dorsal vein in
the hand with physiological saline. It took 8–9 h. Patients were hos-
pitalized for one day to monitor temperature and conduct blood
count tests for adverse reactions following treatment. After 3
months, all subjects received a 2nd treatment with SCE therapy, as
described above. Follow-up visits were scheduled 2, 8, 12, 18, 26,
40 and 56 weeks after treatment for clinical assessments and labora-
tory tests (Fig. 2). Previous work demonstrated that patients receiv-
ing sham therapy did not show changes in immune modulation
(Zhao et al., 2012).ow chart.
Fig. 2.Diagramof SCE therapy for the treatment and follow-up studies. All the participants received two treatmentswith the SCE therapy. Human cord blood units were derived fromhealthy
allogeneic donors. The preparation of CB-SC cultures SCE devices were cultured in serum-free culture medium and incubated at 37 °C, in 8% CO2. After 2–3 weeks, CB-SCs growing at 90%
conﬂuence were prepared for clinical trial. One Educator device was generated from one cord blood unit, and used for one subject at one treatment. Follow-up visits were scheduled 2, 8,
12, 18, 26, 40 and 56weeks after treatment for clinical assessments and laboratory tests. Previous work demonstrated that participants receiving sham therapy failed to show changes in
immune modulation (Zhao et al., 2012).
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C-peptide levels were examined at baseline and after treatments with
SCE therapy. The glucagon-stimulated C-peptide test was performed
as previously described (Gjessing et al., 1987). Glucagon (1 mg, i.v.)
was administrated within 30 s, and six minutes later, plasma samples
were collected for the C-peptide test by Ultrasensitive C-peptide ELISA
kit (Mercodia, Uppsala, Sweden).
2.3. Study End Points
The primary study end points were feasibility and safety of the SCE
therapy through 56 weeks post-treatment and preliminary evaluation
of the efﬁcacy of the therapy for changing immunemarkers in T1D sub-
jects. The secondary study end point was preliminary evidence for efﬁ-
cacy of the therapy in the improvement of β-cell function. Baseline
blood samples were collected prior to SCE therapy.
2.4. Mixed Leukocyte Reactions (MLR) and Ex Vivo Co-cultures
Humanbuffy coat blood unitswere purchased from the Blood Center
of New Jersey (East Orange, NJ). Human peripheral blood-derived
mononuclear cells (PBMC) were harvested as previously described
(Zhao et al., 2012, 2013). To examine the immune modulating effects
of CB-SCs on T cells via themixed leukocyte reactions (MLR), responder
cells were co-cultured with allogeneic stimulator cells irradiated at
3000 rad at the R:S ratio of 1:2, in the presence or absence of CB-SCs.
The ratio of CB-SCs:responder was 1:10. After 4–5 days of co-culture,
cells were photographed with an Olympus IX71 inverted microscope
and collected for ﬂow analysis.
To analyze the CCR7 expression on CD45RO+CD62L− TEM cells,
adult peripheral blood-mononuclear cells (PBMCs) were cocultured
with CB-SCs at the CB-SCs:PBMCs ratio of 1:10 in serum-free culture
medium (Lonza, Walkersville, MD) and incubated at 37 °C, in 8% CO2.
The untreated PBMCs served as control. The CB-SC-treated PBMCs
were collected for ﬂow cytometry at 24 and 48 h respectively.
To perform ex vivo studies, human cord blood units were provided
by Cord:Use Cord Blood Bank (Orlando, FL). Only pathogen-free cord
blood units were used for isolating CB-SCs. Human cord blood-derived
stem cells (CB-SCs)were generated as previously describedwith the fol-
lowing modiﬁcations (Zhao et al., 2012, 2013). Cord blood mononuclear
cells were plated in serum-free culture medium (Lonza, Walkersville,
MD) and incubated at 37 °C, in 8% CO2. After 2–3 weeks, CB-SCs growing
at 80–90% conﬂuence were prepared for co-culture with allogeneic
lymphocytes.2.5. Flow Cytometry
In preparation for the clinical trial, peripheral blood samples (10 ml
per subjects)were obtained frompatients before the treatment and at 2,
8, 18, 26 and 56weeks respectively post-treatment. Cells were incubat-
edwithmouse anti-humanmAbs (BioLegend, SanDiego, CA), including
PerCP/Cy5.5-conjugated anti-CD3, PerCP/Cy5.5-conjugated anti-CD4,
PE-conjugated anti-CD8, FITC-conjugated anti-CD45RA, PE-conjugated
anti-CD45RO, PE-conjugated anti-CD56, APC-conjugated anti-CCR7. To
test the percentage and absolute cell numbers of different subsets in pe-
ripheral blood, cells were immunostained with BD MultiTEST reagents
CD3 FITC/CD8 PE/CD45 PerCP/CD4 APC and CD3 FITC/CD16 + CD56
PE/CD45 PerCP/CD19 APC (BD Biosciences, San Jose, CA) according to
the manufacture's recommended protocols. Isotype-matched mouse
anti-human IgG antibodies (Beckman Coulter) served as a negative con-
trol for all ﬂuorescein-conjugated IgG mAb. After staining, cells were col-
lected and analyzed using a BD FACScalibur™ Cytometer. The ﬁnal data
were analyzed using the CellQuest Pro Software (Becton Dickinson, MD).
For ex vivo studies, ﬂow cytometric analyses were performed as
previously described (Zhao et al., 2009). Cells were stained for 30 min
at room temperature and then washed with PBS prior to ﬂow analysis.
We used several mouse anti-humanmonoclonal Abs (mAbs), including
APC-AF 750-conjugated anti-CD4, APC-AF 750- or Krome Orange-
conjugated anti-CD8, PE- or FITC-conjugated anti-CD45RA, FITC-
conjugated anti-CD45RO, ECD-conjugated anti-CD62L, and PE-Cy7-
conjugated anti-CCR7. Isotype-matched mouse anti-human IgG
antibodies (Beckman Coulter) served as a negative control for all
ﬂuorescein-conjugated IgG mAb. After staining, cells were collected
and analyzed using a Gallios Flow Cytometer (Beckman Coulter),
equipped with 3 lasers (488 nm blue, 638 red, and 405 violet lasers)
for the concurrent reading of up to 10 colors. The ﬁnal datawere analyzed
using the Kaluza Flow Cytometry Analysis Software (Beckman Coulter).2.6. Statistics
An intention-to treat approach was used, with 15 patients undergo-
ing SCE therapy. All participants were included in safety analyses. The
feasibility of the SCE therapy was assessed by analyzing the number of
the patients unable to complete the therapy and the number of patients
whowere lost to follow-up prior to the 12-month visit. The primary ef-
ﬁcacy end points were the change in immune markers between base-
line and follow-ups. Statistical analyses of data were performed by the
two-tailed paired Student's t-test to determine statistical signiﬁcance
2028 E. Delgado et al. / EBioMedicine 2 (2015) 2024–2036between baseline and follow-ups. Values were given as mean ± SD
(standard deviation).
3. Results
3.1. Safety Proﬁle and Feasibility of Two Treatments With SCE Therapy in
Caucasian T1D Subjects
In previous clinical trials, all subjects received one treatment with
the SCE therapy (Zhao et al., 2012, 2013; Li et al., 2015). Due to the like-
lihood that signiﬁcant numbers of pathogenic autoimmune cells may
have remained in lymph nodes and other tissues, failing to enter into
the bloodstream during the procedure, and thus may have escaped
the exposure to CB-SCs, we added a second treatment three months
following the initial session in these T1D subjects (n = 15, Table 1).
No patients experienced any signiﬁcant adverse events during the
course of the two treatments with SCE therapy or during 56-week
follow-up. During the procedure, only mild discomfort at the site of
venipuncture (the median cubital vein) and some soreness of the arm
were noted for some participants. No fever or rejection was noted dur-
ing follow-up studies.
3.2. Clinical Efﬁcacy of SCE Therapy in the Modulation of Memory T Cell
Compartment of T1D Subjects
To evaluate the immune modulating effects of the SCE therapy, we
used ﬂow cytometry to examine immune markers in 15 participants
following SCE therapy. Clinical data indicated no changes in total cell
numbers of each cell population during one-year follow-up, including
leukocyte common antigen CD45+ nuclearized cells, CD3+ T cells,
CD4+ T cells, CD8+ T cells, CD56+ NK cells, and CD20+ B cells (Fig.
3a). Quantiﬁcation of the percentages of total CD4+ and CD8+ T cells
in peripheral blood remained very stable over a year (Fig. 3b). Next,
we explored the modulation of SCE therapy on different T-cell subpop-
ulations by using the common surface markers for characterization of
the naïve and memory T cells, such as CD45RA and CCR7 (Maecker
et al., 2012) (Fig. 3c). Notably, the percentage of naïve CD4+ T
(CD45RA+ CCR7+) cells was signiﬁcantly increased at 26 weeks after
the treatmentwith SCE therapy (41.1±12.5 versus 32.6±11.2 at base-
line, P= 0.0042), and maintained through the ﬁnal follow-up (44.3 ±
8.5 at 56 weeks post-treatment versus the baseline level, P= 0.0021)
(Fig. 3d). The percentage of naïve CD8+ T cells did not exhibit signiﬁcant
changes at any follow-ups (Fig. 3d) (30.74 ± 8.54 at 56 weeks post-
treatment versus 26.62 ± 14.2 at baseline, P = 0.35). These ﬁndings
suggested that the SCE therapy restored the regeneration of naïve
CD4+ T cells, an essential part of normal immune capacity.
To explore the effects of the SCE therapy on thememory T cells, TCM
and TEM were examined by ﬂow cytometry. Overall analysis in these
subjects demonstrated that the percentage of CD4+ TCM (CD45RA−
CCR7+) cells was markedly and constantly increased after receiving
SCE therapy at 18 weeks (38.71 ± 11.7 versus 26.5 ± 15.4 at baseline,
P= 0.018) (Fig. 3e). In contrast, the percentage of CD8+ TCM cells was
only temporarily improved at 18 weeks (16.78 ± 10.5 versus 9.8 ±
8.8 at baseline, P= 0.034), but return to baseline levels during contin-
ued follow-ups (Fig. 3e). In comparison with Group B subjects (4/9,
44%), Group A subjects (4/6, 67%) were more efﬁciently increasing theFig. 3. Changes in immunemarkers in Caucasian T1D patients after SCE therapy. All subjects receiv
with SCE therapy. Follow-up visits were scheduled 2, 8, 12, 18, 26, 40 and 56 weeks after treatm
peripheral blood by Ficoll-Hypaque (γ=1.077) for ﬂow cytometry analyses in T1Dpatients at b
(a) Immune cell quantiﬁcation in peripheral blood. (b) Percentage of CD4+ and CD8+ T cells
different T-cell subpopulations. CD45RA and CCR7 were applied to characterize the naïve and m
of T-cell populations (bottom left panel, orange) and those at 26weeks post-treatment (bottom
T cells in peripheral blood, demonstrating an increase in the percentage of naïve CD4+ T cells at
blood, demonstrating an increase in the percentage of CD4+ TCM cells at 18weeks post treatme
decline in the percentage of CD4+ TEM and CD8+ TEM cells at 18weeks and 26weeks respectivel
decline in their percentages at 26 weeks post treatment. (h) Flow Analysis of CD8+HLA-DR+
treatment.percentage of CD4+ TCM cells over 30% of positive cells at 18 weeks
follow-up (data not shown). Notably, overall analysis of TEM (CD45RA−-
CCR7−) cells revealed that both CD4+ TEM cells and CD8+ TEM cells were
considerably decreased at 18weeks (22.88± 9.4 versus 34.66± 18.48 at
baseline, P=0.03) and 26weeks (20.2±8.8 versus 29.34±11.2 at base-
line, P= 0.015) respectively (Fig. 3f). Group A subjects (6/6, 100%) were
more efﬁciently decreasing the percentage of CD8+ TEM cells over 15% of
positive cells than that in Group B subjects (7/9, 78%) at 26weeks follow-
up; 5/6 (83%) of Group A subjects vs 7/9 (78%) of Group B subjects for the
reduction of CD4+ TEM cells at 26 weeks follow-up (data not shown).
In addition, using HLA-DR as an activationmarker for T cells (Maecker
et al., 2012), clinical data demonstrated that the percentage of CD4+HLA-
DR+ T cells and CD8+HLA-DR+ T cells were markedly declined at
26 weeks follow-up relative to the baseline levels (Fig. 3g and h).
3.3. Up-regulation of CCR7 Expression on T Cells After Receiving SCE Therapy
in T1D Subjects
The C–C chemokine receptor 7 (CCR7) plays important roles in
lymph-node homing of T cells via high endothelial venules andmediat-
ing the T-cell homeostasis (Forster et al., 2008). To further explore the
modulation of SCE therapy, we analyzed the level of CCR7 expression
on naïve T, TCM, and TEM cells by ﬂow cytometry. Clinical data revealed
that both Group A and B subjects signiﬁcantly increased the expression
of CCR7 on Naïve CD4+ T cells (Fig. 4a), naïve CD8+ T cells (Fig. 4b), and
CD4+ TCM cells (Fig. 4c). The marked responses of Naïve CD4+ T cells in
Group A subjects happened as early as at 8 weeks post SCE therapy
(166.08 ± 68.81 at 8 weeks post-treatment versus 60.72 ± 61.62 at
baseline, P = 0.035), comparable to that of delayed responses in
Group B subjects at 26 weeks (251.04 ± 75.71 versus 101.59 ±
94.32 at baseline, P = 0.002) (Fig. 4a). The up-regulation of CCR7 ex-
pression on naïve CD8+ T cells was shown simultaneously at 8 weeks
follow-up in both Group A and B subjects (Group A: 176.36 ±
139.14 at 2 weeks post-treatment versus 92.7 ± 43.98 at baseline,
P= 0.019; Group B: 215.91 ± 87.06 at 8 weeks post-treatment versus
108.95 ± 68.94 at baseline, P = 0.02) (Fig. 4b). The expression of
CCR7 on CD8+ TCM cells in Group A subjects was also improved and
started at 18 weeks follow-up (67.91 ± 11.24 versus 37.33 ± 8.88 at
baseline, P = 0.001) (Fig. 4d), but with a postponed response in
Group B subjects at 56 weeks follow-up (64.89 ± 5.86 versus 42.2 ±
19.83 at baseline, P=0.046) (Fig. 4d). The levels (meanﬂuorescence in-
tensity) of CCR7 expression on both CD4+ TEM and CD8+ TEM cells were
markedly enhanced at 56 weeks follow-up after receiving SCE therapy
in both groups (Fig. 4e). The data suggest that the up-regulation of
CCR7 expression on CD4+ and CD8+ T cells may lead to the re-
distribution of T cells in T1D subjects after the treatment with SCE
therapy.
3.4. Up-regulation of CCR7 Expression on T Cells by ex Vivo Studies After the
Treatment with CB-SCs
CCR7 is a critical marker for the characterization of different T-cell
subpopulations, which expression can bemodulated bymultiple factors
(Britschgi et al., 2008). To further demonstrate the up-regulation of
CCR7 on naïve T, TCM and TEM cells, the mixed leukocyte reaction
(MLR) was employed to in the presence or absence of CB-SCs. Phase-ed two treatments with SCE therapy. After 3 months, all subjects received a 2nd treatment
ent for clinical assessments and laboratory tests. Patient lymphocytes were isolated from
aseline and different time points after SCE therapy. Isotype-matched IgG served as control.
in peripheral blood. (c) Outline of the markers and approach for the characterization of
emory T cells in the gated CD4+ (R2) T cells. Flow cytometry showed the baseline levels
right panel, green) in the PBMCs of T1Dpatient. (d) FlowAnalysis of naïve CD4+ andCD8+
26weeks post treatment. (e) Flow Analysis of CD4+ TCM and CD8+ TCM cells in peripheral
nt. (f) Flow Analysis of CD4+ TEM and CD8+ TEM cells in peripheral blood, demonstrating a
y post treatment. (g) FlowAnalysis of CD4+HLA-DR+ in peripheral blood, demonstrating a
T cells in peripheral blood, demonstrating a decline in their percentages at 26 weeks post
2029E. Delgado et al. / EBioMedicine 2 (2015) 2024–2036
2030 E. Delgado et al. / EBioMedicine 2 (2015) 2024–2036contrast microscopy revealed signiﬁcant numbers of cell clusters of
varying sizes ﬂoating in the supernatant in the absence of CB-SC (Fig.
5a, left panel), but not in the presence of CB-SC (Fig. 5a, right panel).
This indicated the suppressive activity of CB-SCs on the proliferation
of T cells. Flow cytometry showed that the overall levels of CCR7 expres-
sion on CD4+ and CD8+ T cells were increased after the treatment with
CB-SCs (Fig. 5b).We further analyzed theCCR7expressions on the gated
CD4+ T cells. In comparison with CB-SC-untreated groups (responder
only or responder + stimulator), both percentage and mean ﬂuores-
cence intensity (MFI) of CCR7 expression were enhanced on naïve T
(CD45RA+CCR7+) in the CB-SC-treated groups (responder +
stimulator + CB-SCs or responder + CB-SCs) (Fig. 5c, left panels). The
percentage of TCM cells (CD45RO+CCR7+) was increased in the CB-
SC-treated groups; By contrast, the percentage of TEM cells (CD45RO+-
CCR7−) was decreased in the CB-SC-treated groups (Fig. 5c, right
panels). The mean ﬂuorescence intensity of CCR7 expression on TEM
cells (CD45RO+CCR7−) was up-regulated from 1.85 ± 0.07 in the
CB-SC-untreated groups to 2.24 ± 0.01 in the CB-SC-treated groups
(P= 0.017).
To further conﬁrm the up-regulation of CCR7 expression on TEM
cells, another major lymph node homing receptor CD62L was applied
as a marker for human TEM cells (CD45RO+CD62L−) (Lefrancois,
2006; Unsoeld and Pircher, 2005). After treatment with CB-SCs, the
level of CCR7 expression was analyzed on the gated CD45RO+CD62L−
TEM cells. The data demonstrated that the mean ﬂuorescence intensity
of CCR7 expression on CD45RO+CD62L− TEM cells was upregulated
from the baseline level 1.87 ± 0.04 to 2.09 ± 0.07 after the treatment
with CB-SCs (P= 0.02). Therefore, these data suggested that the CCR7
expression on TEM cells can be modulated by the treatment of CB-SCs.
3.5. Clinical Efﬁcacy of SCE Therapy in the Improvement of Islet β Cell
Function of T1D Subjects
To test the therapeutic potential of SCE therapy in the metabolic
control of Caucasian T1D subjects, islet β-cell function was examined
through the measurement of fasting plasma C-peptide and glucagon-
stimulated C-peptide levels. In Group A subjects, clinical results demon-
strated up-regulation of both fasting and glucagon-stimulated C-peptide
levels at 12weeks in two recent-onset T1D subjects (i.e., thosemost likely
to have residual β cell populations) (Fig. 6a and b). Recovered fasting and
glucagon-stimulated C-peptide levels were retained in subject 1 through
the ﬁnal follow-up at 56 weeks post-treatments (Fig. 6a). Glucagon-
stimulated C-peptide levels in subject 2 were stable during one-year
follow-up, while fasting C-peptide levels declined slightly (Fig. 6b). Sub-
ject 3whohadT1D10years at the timeof study, still achievedmodest im-
provements including an increase in fasting C-peptide from 0.25 ng/ml at
basal to 0.36 ng/ml at 56 weeks and an increase in glucagon-stimulated
C-peptide level from 0.4 ng/ml at basal to 0.52 ng/ml at 26 weeks (Fig.
6c). Subject 4 who had T1D 3 years at the time of the study, retained
normal β-cell function with no signiﬁcant change over time in fasting
C-peptide levels from 1.05 ng/ml at baseline to 0.88 ng/ml at 40 weeks
and in glucagon-stimulated C-peptide levels from 2.18 ng/ml at baseline
to 2.01 ng/ml at 40 weeks (Fig. 6d). Interestingly, we found both subjects
5 and 6 displayed some residual isletβ-cell function beyond 10 years after
diagnosis of T1D. After receiving SCE therapy, fasting C-peptide levels in
Subject 5 initially decreased from 0.23 ng/ml at baseline to 0.14 ng/ml
at 26 weeks but increased to 0.3 ng/ml at 40 weeks (Fig. 6e); fasting
C-peptide levels in Subject 6 initially declined from 0.26 ng/ml at baseline
to 0.09 ng/ml at 26 weeks but improved to 0.21 ng/ml at 40 weeks (Fig.
6f). Their glucagon-stimulated C-peptide levels showed the similar
tendencies as the fasting C-peptide levels. In summary, participants in
Group A (that is, subjects with some residual islet β cell function) main-
tained their fasting C-peptide levels at 56 weeks post-treatment
(0.46 ± 0.33 ng/ml versus 0.52 ± 0.34 ng/ml at baseline, P = 0.78)
(Table 2). Consistently, the median daily doses of insulin (0.37 ±
0.16 U/kg body weight versus 0.38 ± 0.16 at baseline, P = 0.84) andthe median glycated hemoglobin (HbA1C) (7.8 ± 1.48 versus 7.6 ±
1.3 at baseline, P= 0.81) were stabilized after 56 weeks post-treatment
(Table 3). The data indicate that the residualβ cell function inGroupApa-
tients was rescued and preserved after receiving SCE therapy, without a
signiﬁcant linear decline as the natural history of T1D (Battaglia and
Atkinson, 2015).
Additionally, no changeswere observed in fasting C-peptide levels of
severe long-standing Group B patients with no residual pancreatic islet
β cell function after receiving two SCE therapies (Tables 2 and 3). Their
responses to SCE therapywere strikingly different from that reported in
long-standing severe Chinese T1D subjects (Zhao et al., 2012; Zhao,
2012). The potential mechanisms underlying this difference need to
be explored.
4. Discussion
Overcoming autoimmune memory is essential for eliminating auto-
immunity in T1D and other autoimmune diseases. The current studies
demonstrated the safety and feasibility of a two-treatment approach
with SCE therapy, without signiﬁcantly changing the numbers and ra-
tios of different cell compartments in the subjects' immune system.
Both the percentage of CD4+ TEM and CD8+ TEM cells were substantially
decreased in the peripheral blood of these Caucasian T1D subjects of
European background after receiving SCE therapy, whereas the CD4+
TCM appeared to be favored by SCE therapy. Notably, the levels of
CCR7 expression on naïve T and TCM cells were markedly increased
after SCE therapy, further conﬁrmed by ex vivo studies. The percentage
of CCR7+ TCM increased at the expense of CCR7− TEM. These ﬁndings
provide a novel solution to alter the autoimmune memory compart-
ment in T1D.
Naïve T cells constantly recirculate between secondary lymphoid
tissue (SLT) using the blood and lymph as conduits. The present study
revealed that the percentage of naïve CD4+ T cells was markedly in-
creased in T1D subjects after receiving SCE therapy. The number of
total CD4+ T cells was constantlymaintained in peripheral blood during
one-year follow-up. Due to the short lifespan (3 months) for most T
cells, the data suggest that the expansion of naïve CD4+ T cells repre-
sented a normal restoration of immune system balance to the T1D sub-
jects by SCE therapy. Clinical evidence demonstrates that population of
TEM is increased in chronic inﬂammation or autoimmune diseases, such
as chronic rhinosinusitis (Pant et al., 2013) and long-standing T1D sub-
jects (Matteucci et al., 2011). Additionally, both the percentage and ab-
solute cell number of naïve T cells and TCM were reduced in long-
standing T1D subjects (Matteucci et al., 2011). Notably, the present clin-
ical data demonstrated that the percentage of Naïve CD4+ T cells and
TCM were all signiﬁcantly increased, but CD4+ TEM and CD8+ TEM de-
clined in these T1D subjects after receiving SCE therapy. Thus, the data
demonstrate that SCE therapy corrected the dysfunction of TEM and fa-
vored the differentiation of TCM in long-standing T1D subjects. Differ-
ently, both CD4+ TCM and TEM, together with CD8+ TCM (but not CD8+
TEM), were all decreased by the treatment of new-onset T1D patients
with Alefacept therapy in T1DAL trial, an approach that use the geneti-
cally engineered fusion protein targeting and deleting CD2+ T cells
(Rigby et al., 2013).
Insulitis is the predominant pathological feature in pancreatic islets
of T1D subjects caused by the inﬁltration of autoimmune CD8+ and
CD4+ T cells, CD20+ B cells, and macrophages (Campbell-Thompson
et al., 2013; In't, 2011). TCM cells trafﬁcking in peripheral bloodmaintain
the capacity to home to lymphnodes due to retained expression of CCR7
and CD62Lmolecules, which are required for migration from blood into
lymphnodes across the high endothelial venules. Notably, current study
revealed the modulation of CCR7 expression on CD4+ TCM, CD8+ TCM,
CD4+ TEM, and CD8+ TEM cells after receiving SCE therapy in T1D sub-
jects. These outcomes may lead to the evacuation of autoimmune cells
from insulitic lesions through lymphatic vessels which express CCL19
and CCL21, the two ligands of CCR7 (Fig. 7). Additionally, the
Fig. 4. Up-regulation of CCR7 expression on T cells in Caucasian T1D patients after SCE therapy. All subjects received two treatments with SCE therapy. After 3 months, all subjects received a
2nd treatmentwith SCE therapy. Follow-up visits were scheduled 2, 8, 12, 18, 26, 40 and 56weeks after treatment for clinical assessments and laboratory tests. Patient lymphocytes were
isolated from peripheral blood by Ficoll-Hypaque (γ= 1.077) for ﬂow cytometry analyses in T1D patients at baseline and different time points after SCE therapy. Isotype-matched IgG
served as control. The levels of CCR7 expression were analyzed by Kaluza Flow Cytometry Analysis Software and present as arbitrary unit (a.u.). (a) Up-regulation of CCR7 expression
on Naïve CD4+ T cells. (b) Up-regulation of CCR7 expression on Naïve CD8+ T cells. (c) Up-regulation of CCR7 expression on CD4+ TCM cells. (d) Up-regulation of CCR7 expression on
CD8+ TCM cells. (e) Modulation of CCR7 expression on CD4+ and CD8+ TEM cells. Data are shown as mean ± SD for all statistical analyses (a–e), paired Student's t test (a–e).
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may contribute to the redistribution and polarization of T cells and re-
sult in the restoration of homeostasis in immune system. Thus, SCE ther-
apy delivers not only the recovery of homeostasis in pancreata, but also
the comprehensive immune balance for the whole body.
In comparisonwith conventional immune therapies (e.g., monoclonal
antibodies, vaccines, Treg therapy, and dendritic cell therapy) for T1D, the
ex vivo immune modulation by CB-SCs inside a device can be controlled
and monitored during the treatment. The lymphocytes (including Naïve
T cells, TCM, and TEM) puriﬁed by apheresis can be intensively educated
by directly contact with CB-SCs, with minimum interference from red
blood cells, granulocytes, and other blood components. This approach
also reduces side effects associated with conventional immune therapies.
Based on our combined preclinical (Zhao et al., 2007, 2009; Zhao and
Mazzone, 2010) and clinical studies (Zhao et al., 2012, 2013) to date,
immunemodulation by CB-SCs seems to bemediated by a variety of mo-
lecular and cellular mechanisms including: 1) Expression of autoimmune
regulator (AIRE) in CB-SCs plays an essential role (Zhao et al., 2012);
2) Functioning via cell–cell contact mechanisms involving the surface
molecule programmed death ligand 1 (PD-L1) (Zhao et al., 2007) and
CD270 on CB-SCs, and their ligands PD-1 and BTLA on variety of immune
cells (e.g., T cells, B cells, monocytes, dendritic cells, and granulocytes (Li
et al., 2015); 3) Acting through soluble factors released by CB-SCs
(e.g., nitric oxide, TGF-β1) (Zhao et al., 2007); and 4) Adjusting the cell–
cell interaction between antigen-presenting cells monocytes/macro-
phages and T cells through co-stimulating molecules and their ligands
(Zhao et al., 2013). Thus, during the ex-vivo brief exposure to CB-SCs,
T1D-derived TCM and TEM can be “educated” by the favorable microenvi-
ronment created byCB-SCs through cell to cell contact and soluble factors.
Previous work demonstrated that a single treatment with SCE ther-
apy can signiﬁcantly improve fasting C-peptide levels, reduce themedi-
an glycated hemoglobin A1C (HbA1C) values, and dramatically decrease
the median daily dose of insulin in Chinese patients with some residual
β cell function and patients with no residual pancreatic islet β cell
function (Zhao et al., 2012). Consistently, we found the regeneration
of islet β cells in SCE-treated long-standing Chinese T2D subjects
(Zhao et al., 2013), which express a shortage of islet β cells similar to
T1D subjects. The current study demonstrated up-regulation of fasting
and glucagon-stimulated C-peptide levels in Caucasian T1D subjects
with some residualβ cell function, including subjects with longstanding
T1D. This response to SCE therapy was similar in Chinese T1D subjects,
but the long-standing severe Caucasian T1D subjects with no residual
pancreatic islet β cell function failed to show any increase in fasting C-
peptide. To improve its clinical efﬁcacy, it will be essential to clarify
the molecular and cellular mechanisms underlying these different re-
sponses to the SCE therapy. Ongoing mechanistic studies revealed the
molecular disparities of expression of muscarinic acetylcholine recep-
tors (mAChRs) on human islet β-cell regeneration between Caucasian
and Chinese populations (Figs. S3 and S4). The M2 receptor and otherFig. 5. Conﬁrm the up-regulation of CCR7 expression on T cells by the ex vivo studies. (a) Phase
contrast microscopy shows the formation of cell clusters with different sizes in the mixed
leukocyte reactions (MLR), in absence (left panel) of CB-SCs, but disappeared in presence
(right panel) of CB-SCs. (b and c) Cells from themixed leukocyte reactions were collected
for ﬂow analysis after co-culture for 5 days. Responder cells (R) were co-cultured with
allogeneic stimulator cells (S) in the presence of CB-SCs. The ratio of R:S was 1:2; the
ratio of CB-SCs:R was 1:10. (b) Flow cytometry of CCR7 expression on the gated CD4+ T
cells and CD8+ T cells. The untreated CD4+ lymphocytes showed two populations: one
was positive for CCR7 expression; anotherwas negative (or very dim) for CCR7 expression
(Top left panel). The mean ﬂuorescence intensities of both populations were increased
after treatment with CB-SCs (bottom left panel). (c) Flow cytometry of CCR7 expression
on Naïve CD4+ T cells, CD45RO+CCR7+ TCM and CD45RO+CCR7− TEM in the gated
CD4+ T cells. The data showed the increase of the percentage of Naïve CD4+ T cells and
CD4+ TCM in the presence of CB-SCs. The percentages of CD4+ TEM were decreased after
treatment with CB-SCs.
2033E. Delgado et al. / EBioMedicine 2 (2015) 2024–2036speciﬁc cholinergic markers such as vesicular acetylcholine transporter
(vAChT) and choline acetyltransferase (ChAT) are substantially expressed
on the islet β cells of the Chinese population (Fig. S3). It indicates the
autocrine cholinergic signal involved in the functional regulation of islet
β cells of Chinese population. However, in pancreata of Caucasian popula-
tion, M3 and M5 muscarinic receptors were strongly expressed on the
islet β cells (Molina et al., 2014); pancreatic islet α cells display M2Fig. 6. Effects of SCE therapy onβ-cell function in Caucasian T1D subjects. All subjects received two
at the beginning and 3rd month respectively. Fasting (blue) and glucagon-stimulated C-pepti
glucagon-stimulated C-peptide production, glucagon (1 mg, i.v.) was administrated within 30 s, a
C-peptide ELISA kit. These data were from six T1D subjects with some residual islet β-cell function
in subject 1 through the ﬁnal follow-up at 56 weeks post-treatments in subject 1–4 respectively. (
after diagnosis of T1D. After receiving SCE therapy, fastingC-peptide levels in Subject 5 initially decr
0.09 ng/ml at 26 weeks but improved to 0.21 ng/ml at 40 weeks. Their glucagon-stimulated C-pereceptor and produce cholinergic signal that contributes to the modula-
tion of islet β-cell function via the paracrine pathway (Rodriguez-Diaz
et al., 2011). Additionally, animal studies have shown that parasympa-
thetic innervationmodulates the β-cell proliferation and function of pan-
creatic islets (Lausier et al., 2010; Rodriguez-Diaz et al., 2012), suggesting
a possiblemechanism for differences in response to SCE therapy based on
the different receptor subtypes. TheM2 receptor-mediated signalingmaytreatmentswith SCE therapy (a–f). T1D subjects received two treatmentswith SCE therapy
de levels (brown) were examined at different time points according to the protocol. For
nd six minutes later, plasma samples were collected for the C-peptide test by Ultrasensitive
(Group A). (a–d) Recovered fasting and glucagon-stimulated C-peptide levels were retained
e and f) show subjects 5 and 6 displayed some residual islet β-cell function beyond 10 years
eased, but increased later at 40weeks; fastingC-peptide levels in Subject 6 initially declined to
ptide levels showed the similar tendencies as the fasting C-peptide levels.
Table 3
Changes in HbA1C levels and insulin doses of the T1D subjects after treatment at 12
months.
Patient No. HbA1C Insulin dose (U/kg body weight)
Before treatment 12 m after SCE Before treatment 12 m after SCE
Group A: T1D patients with residual islet β cell function
1 7.1 7.4 0.28 0.29
2 6.3 6.3 0.32 0.30
3 9 9.3 0.52 0.52
4 6.2 5.9 0.18 0.19
5 7.8 8.9 0.4 0.3
6 9.2 9 0.61 0.6
Mean 7.6 7.8 0.38 0.37
(SD) 1.3 1.48 0.16 0.16
Group B: T1D patients with no residual islet β cell function
7 7.1 7.5 0.62 0.63
8 6.2 6 0.72 0.74
9 8.4 7.9 0.92 0.89
10 9.1 8.4 0.79 0.8
11 7.4 7.5 0.56 0.56
12 10.1 9.2 0.58 0.57
13 8.3 6.8 0.51 0.5
14 6.5 6.6 0.71 0.72
15 8.4 8.3 0.96 0.9
Mean 7.94 7.58 0.71 0.7
(SD) 1.26 1 0.16 0.15
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islet β-cell expansion.
Controlling the immune dysfunctions and overcoming the shortage of
islet β cells are two critical steps for the treatment of T1D. Conventional
immunotherapies (e.g., CD3 and CD20 mAb treatments) targeting the
general immune cell compartment usually leads to the absolute decline
of cell numbers due to their broad cytotoxicity. These approaches may
make patientsmore vulnerable to pathogens and certainly raise concerns
about clinical safety and tolerability. SCE therapymodiﬁes rather than de-
stroys the cells responsible for autoimmune responses. Current clinical
data demonstrated the safety and efﬁcacy of the SCE therapy for the im-
mune modulation of Caucasian T1D subjects of European background.
Due to the plasticity of human T cells, the induction of differentiation of
T cells into different functional subsets and the correction of functional
defects of TEM can be efﬁciently achieved through SCE therapy in T1D sub-
jects. SCE therapy provides lasting reversal of autoimmunity that allows
the native improvement of isletβ-cell function in T1D subjectswith resid-
ual β cell function. A better understanding of the molecular disparities of
islet β cells between Caucasian and Chinese populations will provide in-
sight into possible methods for improving treatment efﬁcacy and β cell
recovery in Caucasians with T1Dwho do not have residual β cell function
prior to treatment. SCE therapy may revolutionize the clinical treatment
of diabetes without the safety and ethical concerns associated with con-
ventional approaches.
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